Unprotected left main coronary artery percutaneous coronary intervention in a pediatric patient with cardiac
Rigved V Tadwalkar1, Michael S Lee
1UCLA Medical Center, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095 USA. mslee@mednet.ucla.edu.
Insights
Percutaneous coronary intervention (PCI) offers a viable treatment for cardiac allograft vasculopathy (CAV), even in complex cases like the unprotected left main coronary artery. This approach can be a safe palliative bridge to repeat heart transplantation.
Area of Science:
- Cardiology
- Transplantation Immunology
Background:
- Cardiac allograft vasculopathy (CAV) is a significant long-term complication of orthotopic heart transplant (OHT), affecting up to 50% of patients within 10 years.
- Pediatric OHT recipients with CAV face a poor prognosis, with high mortality rates post-diagnosis.
- Standard treatments like statins, coronary artery bypass grafting, and repeat OHT have limitations.
Observation:
- Percutaneous coronary intervention (PCI) is an alternative for CAV, demonstrating good initial success but with increased risks of major adverse cardiovascular events.
- Data on PCI for CAV involving the unprotected left main coronary artery (ULMCA) is scarce.
- A case report details successful PCI with drug-eluting stents in a pediatric patient with ULMCA CAV.
Findings:
- PCI can be performed safely in select pediatric patients with ULMCA CAV.
- Drug-eluting stents were utilized in the successful treatment of a complex ULMCA CAV case.
- Key factors for successful PCI in ULMCA CAV include patient selection, predictive outcome models, and operator experience.
Implications:
- PCI may serve as a crucial palliative strategy for pediatric heart transplant recipients with advanced CAV, potentially bridging them to re-transplantation.
- Further research is warranted to optimize PCI techniques and patient selection criteria for ULMCA CAV.
- This case highlights the feasibility of advanced interventional strategies in managing challenging post-transplant cardiovascular complications.
Abstract:
Cardiac allograft vasculopathy (CAV) is an immunologically-mediated phenomenon that occurs in up to 50% of patients surviving to 10 years post orthotopic heart transplant (OHT). While the pediatric subgroup of OHT recipients has a lower overall prevalence of CAV, prognosis is poor after development, with a 24% mortality within 2 years of diagnosis. Medical therapy, including statins, remains the mainstay of treatment. Diffuse intimal thickening often precludes coronary artery bypass grafting, while repeat OHT is associated with inferior outcomes including increased mortality. Percutaneous coronary intervention (PCI) is a therapeutic option for CAV with excellent initial success rates, but higher rates of major adverse cardiovascular events. Despite these challenges, PCI may be performed safely and can serve as a palliative bridge for repeat OHT. There is a paucity of data on PCI for CAV of the unprotected left main coronary artery (ULMCA). We report the case of a 13-year-old female with CAV involving the distal bifurcation of the ULMCA who underwent PCI with drug-eluting stents. While these cases are technically challenging, strategies that may predict success include an appropriately selected patient, use of predictive models for outcomes assessment, and operator expertise.
